Business Description
GT Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US36254L1008
Description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 213.93 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 68.3 | |||||
| 3-Year EPS without NRI Growth Rate | 60.5 | |||||
| 3-Year FCF Growth Rate | 49.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.45 | |||||
| Quick Ratio | 1.45 | |||||
| Cash Ratio | 1.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -99.5 | |||||
| Shareholder Yield % | -45.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -203.12 | |||||
| ROA % | -109.88 | |||||
| ROIC % | -3044.89 | |||||
| ROC (Joel Greenblatt) % | -17578.65 | |||||
| ROCE % | -196.32 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.05 | |||||
| Price-to-Tangible-Book | 3.04 | |||||
| EV-to-EBIT | 0.27 | |||||
| EV-to-EBITDA | 0.27 | |||||
| EV-to-FCF | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 3.04 | |||||
| Price-to-Net-Cash | 3.62 | |||||
| Earnings Yield (Greenblatt) % | 370.37 | |||||
| FCF Yield % | -195.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GT Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.344 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 280.5 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 280.5 - 280.5 | ||
| Shares Outstanding (Mil) | 2.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GT Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GT Biopharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
GT Biopharma Inc Frequently Asked Questions
What is GT Biopharma Inc(XPAR:GTBP)'s stock price today?
The current price of XPAR:GTBP is €280.50. The 52 week high of XPAR:GTBP is €280.50 and 52 week low is €280.50.
When is next earnings date of GT Biopharma Inc(XPAR:GTBP)?
The next earnings date of GT Biopharma Inc(XPAR:GTBP) is 2025-03-26 Est..
Does GT Biopharma Inc(XPAR:GTBP) pay dividends? If so, how much?
GT Biopharma Inc(XPAR:GTBP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers